Cargando…
Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial
The purpose of the study was to assess the proportion of patients who achieve pain relief thresholds, the time needed to reach the thresholds, and the relationship between pain and inflammation among patients with rheumatoid arthritis (RA) and an inadequate response to methotrexate in RA-BEAM (NCT01...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617097/ https://www.ncbi.nlm.nih.gov/pubmed/31212775 http://dx.doi.org/10.3390/jcm8060831 |
_version_ | 1783433613108314112 |
---|---|
author | Taylor, Peter C. Lee, Yvonne C. Fleischmann, Roy Takeuchi, Tsutomu Perkins, Elizabeth L. Fautrel, Bruno Zhu, Baojin Quebe, Amanda K. Gaich, Carol L. Zhang, Xiang Dickson, Christina L. Schlichting, Douglas E. Patel, Himanshu Durand, Frederick Emery, Paul |
author_facet | Taylor, Peter C. Lee, Yvonne C. Fleischmann, Roy Takeuchi, Tsutomu Perkins, Elizabeth L. Fautrel, Bruno Zhu, Baojin Quebe, Amanda K. Gaich, Carol L. Zhang, Xiang Dickson, Christina L. Schlichting, Douglas E. Patel, Himanshu Durand, Frederick Emery, Paul |
author_sort | Taylor, Peter C. |
collection | PubMed |
description | The purpose of the study was to assess the proportion of patients who achieve pain relief thresholds, the time needed to reach the thresholds, and the relationship between pain and inflammation among patients with rheumatoid arthritis (RA) and an inadequate response to methotrexate in RA-BEAM (NCT0170358). A randomized, double-blind trial was conducted, comparing baricitinib (N = 487), adalimumab (N = 330), and placebo (N = 488) plus methotrexate. Pain was evaluated by patient’s assessment on a 0–100 mm visual analog scale (VAS). The following were assessed through a 24-week placebo-controlled period: the proportion of patients who achieved ≥30%, ≥50%, and ≥70% pain relief, the time to achieve these pain relief thresholds, remaining pain (VAS ≤ 10 mm, ≤20 mm, or ≤40 mm), and the relationship between inflammation markers and pain relief. Baricitinib-treated patients were more likely (p < 0.05) to achieve ≥30%, ≥50%, and ≥70% pain relief than placebo- and adalimumab-treated patients, as early as Week 1 vs. placebo and at Week 4 vs. adalimumab. A greater proportion of baricitinib-treated patients achieved ≤20 mm or ≤40 mm remaining pain vs. placebo- and adalimumab-treated patients. Baricitinib-treated patients tended to demonstrate consistent pain relief independent of levels of inflammation control. In RA patients with an inadequate response to methotrexate, baricitinib provided greater and more rapid pain relief than adalimumab and placebo. Analyses suggest the relationship between inflammation and pain may be different for baricitinib and adalimumab treatments. |
format | Online Article Text |
id | pubmed-6617097 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-66170972019-07-18 Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial Taylor, Peter C. Lee, Yvonne C. Fleischmann, Roy Takeuchi, Tsutomu Perkins, Elizabeth L. Fautrel, Bruno Zhu, Baojin Quebe, Amanda K. Gaich, Carol L. Zhang, Xiang Dickson, Christina L. Schlichting, Douglas E. Patel, Himanshu Durand, Frederick Emery, Paul J Clin Med Article The purpose of the study was to assess the proportion of patients who achieve pain relief thresholds, the time needed to reach the thresholds, and the relationship between pain and inflammation among patients with rheumatoid arthritis (RA) and an inadequate response to methotrexate in RA-BEAM (NCT0170358). A randomized, double-blind trial was conducted, comparing baricitinib (N = 487), adalimumab (N = 330), and placebo (N = 488) plus methotrexate. Pain was evaluated by patient’s assessment on a 0–100 mm visual analog scale (VAS). The following were assessed through a 24-week placebo-controlled period: the proportion of patients who achieved ≥30%, ≥50%, and ≥70% pain relief, the time to achieve these pain relief thresholds, remaining pain (VAS ≤ 10 mm, ≤20 mm, or ≤40 mm), and the relationship between inflammation markers and pain relief. Baricitinib-treated patients were more likely (p < 0.05) to achieve ≥30%, ≥50%, and ≥70% pain relief than placebo- and adalimumab-treated patients, as early as Week 1 vs. placebo and at Week 4 vs. adalimumab. A greater proportion of baricitinib-treated patients achieved ≤20 mm or ≤40 mm remaining pain vs. placebo- and adalimumab-treated patients. Baricitinib-treated patients tended to demonstrate consistent pain relief independent of levels of inflammation control. In RA patients with an inadequate response to methotrexate, baricitinib provided greater and more rapid pain relief than adalimumab and placebo. Analyses suggest the relationship between inflammation and pain may be different for baricitinib and adalimumab treatments. MDPI 2019-06-12 /pmc/articles/PMC6617097/ /pubmed/31212775 http://dx.doi.org/10.3390/jcm8060831 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Taylor, Peter C. Lee, Yvonne C. Fleischmann, Roy Takeuchi, Tsutomu Perkins, Elizabeth L. Fautrel, Bruno Zhu, Baojin Quebe, Amanda K. Gaich, Carol L. Zhang, Xiang Dickson, Christina L. Schlichting, Douglas E. Patel, Himanshu Durand, Frederick Emery, Paul Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial |
title | Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial |
title_full | Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial |
title_fullStr | Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial |
title_full_unstemmed | Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial |
title_short | Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial |
title_sort | achieving pain control in rheumatoid arthritis with baricitinib or adalimumab plus methotrexate: results from the ra-beam trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617097/ https://www.ncbi.nlm.nih.gov/pubmed/31212775 http://dx.doi.org/10.3390/jcm8060831 |
work_keys_str_mv | AT taylorpeterc achievingpaincontrolinrheumatoidarthritiswithbaricitiniboradalimumabplusmethotrexateresultsfromtherabeamtrial AT leeyvonnec achievingpaincontrolinrheumatoidarthritiswithbaricitiniboradalimumabplusmethotrexateresultsfromtherabeamtrial AT fleischmannroy achievingpaincontrolinrheumatoidarthritiswithbaricitiniboradalimumabplusmethotrexateresultsfromtherabeamtrial AT takeuchitsutomu achievingpaincontrolinrheumatoidarthritiswithbaricitiniboradalimumabplusmethotrexateresultsfromtherabeamtrial AT perkinselizabethl achievingpaincontrolinrheumatoidarthritiswithbaricitiniboradalimumabplusmethotrexateresultsfromtherabeamtrial AT fautrelbruno achievingpaincontrolinrheumatoidarthritiswithbaricitiniboradalimumabplusmethotrexateresultsfromtherabeamtrial AT zhubaojin achievingpaincontrolinrheumatoidarthritiswithbaricitiniboradalimumabplusmethotrexateresultsfromtherabeamtrial AT quebeamandak achievingpaincontrolinrheumatoidarthritiswithbaricitiniboradalimumabplusmethotrexateresultsfromtherabeamtrial AT gaichcaroll achievingpaincontrolinrheumatoidarthritiswithbaricitiniboradalimumabplusmethotrexateresultsfromtherabeamtrial AT zhangxiang achievingpaincontrolinrheumatoidarthritiswithbaricitiniboradalimumabplusmethotrexateresultsfromtherabeamtrial AT dicksonchristinal achievingpaincontrolinrheumatoidarthritiswithbaricitiniboradalimumabplusmethotrexateresultsfromtherabeamtrial AT schlichtingdouglase achievingpaincontrolinrheumatoidarthritiswithbaricitiniboradalimumabplusmethotrexateresultsfromtherabeamtrial AT patelhimanshu achievingpaincontrolinrheumatoidarthritiswithbaricitiniboradalimumabplusmethotrexateresultsfromtherabeamtrial AT durandfrederick achievingpaincontrolinrheumatoidarthritiswithbaricitiniboradalimumabplusmethotrexateresultsfromtherabeamtrial AT emerypaul achievingpaincontrolinrheumatoidarthritiswithbaricitiniboradalimumabplusmethotrexateresultsfromtherabeamtrial |